ES2309299T3 - Tratamiento de la artritis reumatoide usando imatinib. - Google Patents
Tratamiento de la artritis reumatoide usando imatinib. Download PDFInfo
- Publication number
- ES2309299T3 ES2309299T3 ES03704474T ES03704474T ES2309299T3 ES 2309299 T3 ES2309299 T3 ES 2309299T3 ES 03704474 T ES03704474 T ES 03704474T ES 03704474 T ES03704474 T ES 03704474T ES 2309299 T3 ES2309299 T3 ES 2309299T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- study
- sal
- rheumatoid arthritis
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010003246 arthritis Diseases 0.000 title description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 title description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title description 2
- 229960002411 imatinib Drugs 0.000 title description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 60
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000012458 free base Substances 0.000 claims abstract description 12
- -1 4-methylpiperazin-1-ylmethyl Chemical group 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 239000003435 antirheumatic agent Substances 0.000 claims description 16
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 210000001503 joint Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 8
- 229960004618 prednisone Drugs 0.000 description 8
- 206010023232 Joint swelling Diseases 0.000 description 7
- 239000003246 corticosteroid Substances 0.000 description 7
- 229960001334 corticosteroids Drugs 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 230000003356 anti-rheumatic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 210000001179 synovial fluid Anatomy 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940111120 gold preparations Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000023769 AA amyloidosis Diseases 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 1
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000002392 Rheumatic Nodule Diseases 0.000 description 1
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 206010039811 Secondary amyloidosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201882 | 2002-01-28 | ||
| GBGB0201882.8A GB0201882D0 (en) | 2002-01-28 | 2002-01-28 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2309299T3 true ES2309299T3 (es) | 2008-12-16 |
Family
ID=9929858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03704474T Expired - Lifetime ES2309299T3 (es) | 2002-01-28 | 2003-01-27 | Tratamiento de la artritis reumatoide usando imatinib. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060264443A1 (enExample) |
| EP (1) | EP1471916B1 (enExample) |
| JP (1) | JP4398731B2 (enExample) |
| KR (1) | KR101030416B1 (enExample) |
| CN (1) | CN1646130A (enExample) |
| AT (1) | ATE399555T1 (enExample) |
| BR (1) | BR0307286A (enExample) |
| CA (1) | CA2473158C (enExample) |
| DE (1) | DE60321888D1 (enExample) |
| DK (1) | DK1471916T3 (enExample) |
| ES (1) | ES2309299T3 (enExample) |
| GB (1) | GB0201882D0 (enExample) |
| IL (1) | IL162983A (enExample) |
| MX (1) | MXPA04007309A (enExample) |
| NO (1) | NO328255B1 (enExample) |
| NZ (1) | NZ534137A (enExample) |
| PL (1) | PL212137B1 (enExample) |
| PT (1) | PT1471916E (enExample) |
| RU (1) | RU2322238C2 (enExample) |
| SI (1) | SI1471916T1 (enExample) |
| WO (1) | WO2003063844A2 (enExample) |
| ZA (1) | ZA200405323B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003226209B2 (en) * | 2002-03-21 | 2008-10-23 | Dana-Farber Cancer Institute, Inc. | Inhibition of cell death responses induced by oxidative stress |
| US20050130986A1 (en) * | 2003-11-21 | 2005-06-16 | Eklund Kari K. | Treatment of spondylarthropathies |
| US20080248022A1 (en) * | 2004-09-08 | 2008-10-09 | Immunaid Pty Ltd | Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases |
| US20080032989A1 (en) * | 2006-05-31 | 2008-02-07 | Robinson William H | Method of treating inflammatory diseases using tyroskine kinase inhibitors |
| CN102512421B (zh) * | 2011-10-28 | 2013-11-06 | 中国科学院广州生物医药与健康研究院 | 哌嗪酰胺类化合物在制药中的应用 |
| KR101386697B1 (ko) | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| RU2580656C1 (ru) * | 2014-11-20 | 2016-04-10 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения |
| US12173065B2 (en) * | 2018-10-18 | 2024-12-24 | Sinomab Bioscience Limited | Fusion proteins comprising extracellular domain of human CD22 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316884A (en) * | 1979-01-25 | 1982-02-23 | Adria Laboratories, Inc. | Sustained release pharmaceutical formulation |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5792476A (en) * | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6274588B1 (en) * | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
| CO5200760A1 (es) * | 1999-06-16 | 2002-09-27 | Smithkline Beecham Corp | Antagonistas del receptor de la il-8 ceptor il-8 |
| GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
| WO2002083075A2 (en) * | 2001-04-16 | 2002-10-24 | Uab Research Foundation | Akt and regulation of ra synovial fibroblast apoptosis |
| PT1392313E (pt) * | 2001-05-16 | 2007-07-17 | Novartis Ag | Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico |
| EP1401415B1 (en) * | 2001-06-29 | 2006-06-21 | AB Science | Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases |
-
2002
- 2002-01-28 GB GBGB0201882.8A patent/GB0201882D0/en not_active Ceased
-
2003
- 2003-01-27 MX MXPA04007309A patent/MXPA04007309A/es active IP Right Grant
- 2003-01-27 NZ NZ534137A patent/NZ534137A/en not_active IP Right Cessation
- 2003-01-27 JP JP2003563538A patent/JP4398731B2/ja not_active Expired - Fee Related
- 2003-01-27 US US10/502,534 patent/US20060264443A1/en not_active Abandoned
- 2003-01-27 DE DE60321888T patent/DE60321888D1/de not_active Expired - Lifetime
- 2003-01-27 EP EP03704474A patent/EP1471916B1/en not_active Expired - Lifetime
- 2003-01-27 RU RU2004126447/15A patent/RU2322238C2/ru not_active IP Right Cessation
- 2003-01-27 DK DK03704474T patent/DK1471916T3/da active
- 2003-01-27 WO PCT/EP2003/000802 patent/WO2003063844A2/en not_active Ceased
- 2003-01-27 SI SI200331369T patent/SI1471916T1/sl unknown
- 2003-01-27 ES ES03704474T patent/ES2309299T3/es not_active Expired - Lifetime
- 2003-01-27 CN CNA038028808A patent/CN1646130A/zh active Pending
- 2003-01-27 BR BR0307286-0A patent/BR0307286A/pt not_active IP Right Cessation
- 2003-01-27 CA CA2473158A patent/CA2473158C/en not_active Expired - Fee Related
- 2003-01-27 KR KR1020047011580A patent/KR101030416B1/ko not_active Expired - Fee Related
- 2003-01-27 PL PL370264A patent/PL212137B1/pl unknown
- 2003-01-27 PT PT03704474T patent/PT1471916E/pt unknown
- 2003-01-27 AT AT03704474T patent/ATE399555T1/de active
-
2004
- 2004-07-05 ZA ZA2004/05323A patent/ZA200405323B/en unknown
- 2004-07-12 IL IL162983A patent/IL162983A/en not_active IP Right Cessation
- 2004-08-27 NO NO20043585A patent/NO328255B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 US US12/328,013 patent/US20090131382A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1646130A (zh) | 2005-07-27 |
| EP1471916A2 (en) | 2004-11-03 |
| RU2004126447A (ru) | 2005-07-10 |
| US20090131382A1 (en) | 2009-05-21 |
| PT1471916E (pt) | 2008-10-03 |
| KR20040086301A (ko) | 2004-10-08 |
| GB0201882D0 (en) | 2002-03-13 |
| PL370264A1 (en) | 2005-05-16 |
| ZA200405323B (en) | 2005-08-31 |
| BR0307286A (pt) | 2004-12-28 |
| HK1072192A1 (en) | 2005-08-19 |
| ATE399555T1 (de) | 2008-07-15 |
| KR101030416B1 (ko) | 2011-04-20 |
| IL162983A (en) | 2010-06-16 |
| RU2322238C2 (ru) | 2008-04-20 |
| DE60321888D1 (enExample) | 2008-08-14 |
| PL212137B1 (pl) | 2012-08-31 |
| SI1471916T1 (sl) | 2008-12-31 |
| JP2005526022A (ja) | 2005-09-02 |
| EP1471916B1 (en) | 2008-07-02 |
| US20060264443A1 (en) | 2006-11-23 |
| MXPA04007309A (es) | 2005-09-12 |
| WO2003063844A2 (en) | 2003-08-07 |
| WO2003063844A3 (en) | 2004-04-01 |
| NO328255B1 (no) | 2010-01-18 |
| DK1471916T3 (da) | 2008-10-20 |
| JP4398731B2 (ja) | 2010-01-13 |
| CA2473158C (en) | 2013-06-11 |
| NZ534137A (en) | 2007-03-30 |
| NO20043585L (no) | 2004-10-21 |
| CA2473158A1 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2701603T3 (es) | Métodos de tratamiento que utilizan inhibidores selectivos de Bcl-2 | |
| ES2745041T3 (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios | |
| US20090131382A1 (en) | Treatment of rheumatoid arthritis using imatinib | |
| JP2023537403A (ja) | 痛風を治療する方法 | |
| JP2011190199A (ja) | 関節リウマチ薬 | |
| AU2016319292A1 (en) | Use of interleukin 2 for treating spondyloarthritis | |
| ES2880950T3 (es) | Terapia de anticuerpos contra el VIH como sustituto del tratamiento | |
| MXPA02008756A (es) | Terapia adyuvante inmune de virus de inmunodeficiencia humana. | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| US20230089371A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| Adams | New relief for gout | |
| AU2007201056B2 (en) | Treatment of rheumatoid arthritis using imatinib | |
| JP2000256211A (ja) | Ｈｉｖ治療薬 | |
| HK1072192B (en) | Treatment of rheumatoid arthritis using imatinib | |
| WO2021108338A1 (en) | A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis | |
| US20050130986A1 (en) | Treatment of spondylarthropathies | |
| EP3784243B1 (en) | Methotrexate for use as a medicament | |
| AU2003206783A1 (en) | Treatment of rheumatoid arthritis using imatinie | |
| O'Horo | Canakinumab | |
| WO2025209478A1 (en) | Methods of treatment warm autoimmune hemolytic anemia using sovleplenib | |
| Alivernini et al. | Drugs in Focus in Arthritis: Leflunomide | |
| UA12320U (en) | Method for treating patients with rheumatoid arthritis involving heart |